Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgium's UCB and UK-based Domainex have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known as MEK), a protein which is over-active in many human cancers.
Subscribe to our email newsletter
Domainex’s Combinatorial Domain Hunting (CDH) technology is used to identify a form of the MEK protein which can be produced in large quantities and is suitable for structure-based drug discovery.
Domainex research director Trevor Perrior said UCB could successfully utilize the constructs to generate high-resolution structural information and, most importantly, to use it to optimize their chemical series.
Using new structural information, UCB scientists will design a novel class of molecules which inhibit MEK.
Domainex uses unique and proprietary technologies to resolve common bottlenecks facing the pharmaceutical and biotechnology industries in the post-genomic era.